|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,166.50 JPY | +0.25% |
|
+0.72% | +3.51% |
| 07-13 | Pfizer, Astellas Secure FDA Nod For Bladder Cancer Drug | MT |
| 07-10 | Health Care Down on Rotation Back to Tech - Health Care Roundup | DJ |
| Market Cap | 3,881B 23.71B 20.82B 19.37B 17.77B 33.39B 2,283B 33.91B 230B 89.85B 1,123B 89.01B 87.09B | P/E 2027 * |
11.3x | P/E 2028 * | 11.8x |
|---|---|---|---|---|---|
| Enterprise Value | 3,751B 22.92B 20.13B 18.72B 17.18B 32.27B 2,207B 32.77B 222B 86.84B 1,085B 86.03B 84.17B | EV / Sales 2027 * |
1.66x | EV / Sales 2028 * | 1.64x |
| Free-Float |
97.66% | Yield 2027 * |
3.71% | Yield 2028 * | 3.83% |
Last Transcript: Astellas Pharma Inc.
| 1 day | +0.25% | ||
| 1 week | +0.72% | ||
| Current month | -0.39% | ||
| 1 month | +0.91% | ||
| 3 months | -12.22% | ||
| 6 months | -4.22% | ||
| Current year | +3.51% |
| 1 week | 2,131.5 |  | 2,218 |
| 1 month | 2,105 | | 2,218 |
| Current year | 2,041 | | 2,717 |
| 1 year | 1,475 | | 2,717 |
| 3 years | 1,243.5 | | 2,717 |
| 5 years | 1,243.5 | | 2,717 |
| 10 years | 1,243.5 | | 2,717 |
| Manager | Title | Age | Since |
|---|---|---|---|
Naoki Okamura
CEO | Chief Executive Officer | 63 | 09/02/2023 |
Kitamura Atsushi
DFI | Director of Finance/CFO | 54 | 31/10/2023 |
Tatjana Dragovic
CMP | Compliance Officer | - | 31/03/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Kenji Yasukawa
CHM | Chairman | 66 | 09/02/2023 |
Naoki Okamura
BRD | Director/Board Member | 63 | 31/05/2019 |
| Director/Board Member | 58 | 31/05/2023 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.25% | +0.72% | +46.63% | +4.16% | 23.71B | |
| +0.86% | +1.43% | +47.17% | +161.40% | 1,067B | |
| +1.59% | +4.09% | +56.51% | +52.79% | 635B | |
| +0.95% | +1.91% | +36.30% | +83.13% | 458B | |
| +1.60% | +6.25% | +37.00% | +30.00% | 347B | |
| -0.60% | +1.52% | +36.67% | +39.80% | 295B | |
| -0.14% | +0.60% | +17.29% | +18.19% | 262B | |
| +0.09% | -2.82% | -29.09% | -41.29% | 216B | |
| +1.22% | +2.66% | +22.66% | +59.81% | 203B | |
| -1.18% | -3.70% | +11.28% | +67.43% | 161B | |
| Average | +0.46% | +1.27% | +28.24% | +47.54% | 366.72B | |
| Weighted average by Cap. | +0.76% | +1.94% | +36.06% | +77.67% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 2,261B 13.81B 12.13B 11.28B 10.35B 19.45B 1,330B 19.75B 134B 52.34B 654B 51.85B 50.73B | 2,075B 12.67B 11.13B 10.35B 9.5B 17.85B 1,221B 18.12B 123B 48.03B 600B 47.58B 46.56B |
| Net income | 344B 2.1B 1.85B 1.72B 1.57B 2.96B 202B 3B 20.38B 7.96B 99.47B 7.89B 7.72B | 327B 2B 1.76B 1.63B 1.5B 2.82B 193B 2.86B 19.4B 7.58B 94.72B 7.51B 7.35B |
| Net Debt | -130B -795M -698M -649M -596M -1.12B -76.52B -1.14B -7.71B -3.01B -37.62B -2.98B -2.92B | -472B -2.89B -2.53B -2.36B -2.16B -4.06B -278B -4.13B -27.98B -10.93B -137B -10.83B -10.6B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24/07/26 | JP¥2,166.50 | +0.25% | 4,657,000 |
| 23/07/26 | JP¥2,161.00 | -0.67% | 4,744,700 |
| 22/07/26 | JP¥2,175.50 | -0.96% | 7,982,000 |
| 21/07/26 | JP¥2,196.50 | +2.12% | 9,078,900 |
| 17/07/26 | JP¥2,151.00 | +0.14% | 10,798,400 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 4503 Stock
Select your edition
All financial news and data tailored to specific country editions
